Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare Dysport® and Botox® in the Treatment of Cervical Dystonia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients ≥ 18 years of age of both genders,~* Cervical dystonia~* symptoms with a minimum duration of 18 months,~* Negative pregnancy test in sexually active women,~* Able to participate in the study (understand goals of botulinum toxin A treatment and sign Informed Consent Form).~Exclusion Criteria:~* Patient with cervical contractures~* Known significant underlying dysphasia~* Patients who have received botulinum toxin treatment within the past 4 months.~* Contraindication to botulinum toxin treatment~* Any disease that might affect neuromuscular function (Myasthenia Gravis, Eaton-Lambert syndrome, ALS ...)~* Patients who have received oral anti-spasticity medication, phenol therapy, myotomy or denervation surgery, deep brain stimulation for cervical dystonia,~* Patients who required more than 500 units of Dysport or 200 units of Botox.~* Any concomitant treatment that could interfere with the action of botulinum toxin,~* Subjects having participated within the last 3 months or currently participating in an investigational drug study,~* Pregnancy,~* Lactation.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Dysport® to Botox® (Type: EXPERIMENTAL): Dysport® injection in first intervention period and Botox® in second intervention period (after washout period) cross over injection of Dysport® (abobotulinumtoxinA) and Botox® (onabotulinumtoxinA)
- Botox® to Dysport® (Type: EXPERIMENTAL): Botox® injection in first intervention period and Dysport® in second intervention period (after washout period) cross over injection of Dysport® (abobotulinumtoxinA) and Botox® (onabotulinumtoxinA)

Based on this trial design, predict the completion outcome and termination type (if applicable).